SWITCH-26 Study: A Longitudinal Questionnaire Study on the Impact of Switching to a 26-Week Injectable Therapy on Convenience and Psychological Burden in Patients with Bronchial Asthma

SWITCH-26 Study: A Longitudinal Questionnaire Study on the Impact of Switching to a 26-Week Injectable Therapy on Convenience and Psychological Burden in Patients with Bronchial Asthma - SWITCH-26 Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061809

Enrollment

Registered

2026-06-05

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20 years or older at the time of consent Patients who have been receiving the same biologic therapy (omalizumab, mepolizumab, benralizumab, dupilumab, or tezepelumab) for at least 12 months at the time of consent Patients who switch to a long-acting injectable therapy administered every 26 weeks Patients who provide written informed consent after receiving sufficient explanation of the study

Exclusion criteria

Exclusion criteria: Patients who changed biologic therapy within 12 months prior to consent Patients who received unapproved biologic therapies within 12 months prior to consent Patients who received pharmacological treatment for malignancy within 12 months prior to consent Patients deemed inappropriate for participation by the investigator

Design outcomes

Primary

Measure	Time frame
Change in treatment satisfaction score from baseline (prior to switching) to 6 months after switching to a long-acting injectable therapy, assessed using a questionnaire.	—

Secondary

Measure	Time frame
Change in convenience score (baseline, 6 months, and 12 months; questionnaire using a 5-point Likert scale) Change in psychological burden score (baseline, 6 months, and 12 months; questionnaire using a 5-point Likert scale) Change in treatment satisfaction score (baseline, 6 months, and 12 months; questionnaire using a 5-point Likert scale) Change in the proportion of patients achieving clinical remission (baseline and 12 months) Change in the number of asthma exacerbations (comparison between 12 months before and 12 months after switching) Change in Asthma Control Test (ACT) score (baseline, 6 months, and 12 months) Change in lung function (FEV1) (baseline, 6 months, and 12 months) Change in peripheral blood eosinophil count (baseline, 6 months, and 12 months)	—

Measure

Time frame

Change in convenience score (baseline, 6 months, and 12 months; questionnaire using a 5-point Likert scale) Change in psychological burden score (baseline, 6 months, and 12 months; questionnaire using a 5-point Likert scale) Change in treatment satisfaction score (baseline, 6 months, and 12 months; questionnaire using a 5-point Likert scale) Change in the proportion of patients achieving clinical remission (baseline and 12 months) Change in the number of asthma exacerbations (comparison between 12 months before and 12 months after switching) Change in Asthma Control Test (ACT) score (baseline, 6 months, and 12 months) Change in lung function (FEV1) (baseline, 6 months, and 12 months) Change in peripheral blood eosinophil count (baseline, 6 months, and 12 months)

—

Countries

Japan

Contacts

Public ContactHironobu Tsubouchi

University of Miyazaki Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Me

hironobu_tsubouchi@med.miyazaki-u.ac.jp0985852965

Outcome results